• Wednesday, Nov 25, 2020
  • Last Update : 04:05 pm

Preliminary results show Chinese Covid-19 vaccine candidate safe

  • Published at 02:29 pm October 17th, 2020
Covid-19 vaccine
File photo: A booth, displaying a Covid-19 vaccine candidate from China National Biotech Group (CNBG), is seen at the 2020 China International Fair for Trade in Services (CIFTIS), in Beijing on September 5, 2020 Reuters

Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59

A Chinese Covid-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomised clinical trial published on Thursday in The Lancet Infectious Diseases journal.

The latest study included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients. 

Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59.

The trial was not designed to assess efficacy of the vaccine, so it is not possible to say whether the antibody responses induced by the vaccine, called BBIBP-CorV, are sufficient to protect people from SARS-CoV-2 infection.

The authors also noted that interpretation of the results of this study is limited by the short duration of follow-up.

According to The Lancet, there are currently 42 vaccines for Covid-19 in clinical trials. Vaccine candidates in clinical trials vary in type and include DNA plasmid vaccines, inactivated virus vaccines, adenovirus-vectored vaccines, RNA vaccines, protein subunit vaccines and virus-like particle vaccines. Some of these have already proved safe and able to elicit immune responses in early phase clinical trials.

"Our findings indicate that a booster shot is necessary to achieve the greatest antibody responses against SARS-CoV-2 and could be important for protection. 

This provides useful information for a phase 3 trial," said Yang Xiaoming, one of the authors of the study and a professor from the Beijing Institute of Biological Products.

 


54
52
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail